Navigation Links
Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data

  • Nine out of 10 non-diabetic patients treated with Exforge achieved recommended blood pressure goals[1]
  • Additional average decrease of 20 mmHg in systolic blood pressure observed in patients taking Exforge over reductions seen with previous monotherapy[1]
  • Nearly 70% of those with high blood pressure not at treatment target levels[2] and most require two or more medications to achieve goal[2]
BASEL, Switzerland, May 21, 2007 - Exforge®, a single-tablet combination of two of the world's most commonly prescribed high blood pressure medicines[3],[4], has been shown in new clinical data to have helped nine out of 10 non-diabetic patients to reach their treatment goals after having previously failed to do so with single medicines[1].
The results showed patients taking Exforge experienced on average an additional 20 mmHg drop in systolic blood pressure compared to reductions seen with their previous medication[1]. The data from this trial involving 894 patients were presented today at the Annual Scientific Meeting of the American Society of Hypertension (ASH) in Chicago.
The efficacy of Exforge, which combines the angiotensin receptor blocker (ARB) valsartan (Diovan®) and the calcium channel blocker (CCB) amlodipine in one tablet, was again demonstrated in this trial, even in patients considered to be more difficult to treat such as the elderly or those with type 2 diabetes[1]. Exforge was well-tolerated at the doses used in this trial[1].
The study - designed to assess the use of Exforge in a real-life treatment environment - showed that patients who had failed to reach the recommended blood pressure goal of 140/90 mmHg (systolic/diastolic pressure) on a range of si
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
2. Study Suggests Invega Helps Patients With Schizophrenia Maintain Symptom Control
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
5. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
10. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
11. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Post Your Comments:
(Date:7/30/2015)... 30, 2015  EP Global Communications, Inc. (Public OTC: ... contacted the Company about discussing EPGL,s electronic contact ... Monday, August 3, 2015.  Novartis CEO Joe ... the coming electronic contact lens market could be ... next several years.  Novartis partnered with Google in ...
(Date:7/30/2015)... OAKS, Calif., July 30, 2015  Amgen (NASDAQ: ... the second quarter of 2015. Key results include: ... the second quarter of 2014 to $5,370 million, ... by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable changes ...
(Date:7/30/2015)... July 30, 2015  Cleveland Clinic President Wael ... address last month that industry is compelled to adopt ... gain the efficiencies—and develop the transformational innovations -- required ... comments were preceded by Doug Kohrs , past ... moderator, who stressed that industry must add "episode of ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2
... SAN CARLOS, Calif., June 23, 2011 PharmacoFore, ... abuse-resistant prescription drugs, today announced positive results from ... its hydromorphone (HM) Bio-Activated Molecular Delivery™ (Bio-MD™) product ... will present at the 2011 BIO Business Forum ...
... Today,s U.S. Supreme Court decision in ... safety, giving generic drug companies legal immunity when they ignore ...  This decision eliminates any incentive for generic manufacturers to ensure ... drugs, potential dangers. This decision also means that ...
Cached Medicine Technology:PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was 2PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was 3PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was 4Generic Drug Decision Disastrous to Patient Safety 2
(Date:7/31/2015)... ... July 31, 2015 , ... As part of their company mission, ... of animal welfare organizations is essential to the longevity of their business. It ... National Association of Professional Pet Sitters (NAPPS) annual Presents 4 Pets supply drive. ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... “HARMONY 2015”, one of the industry’s premier thought leadership symposiums, hosted by ... and 6. The event attracts over 250 “C”-level executives, administrators, directors of ...
(Date:7/31/2015)... IL (PRWEB) , ... July 31, 2015 , ... The ... Boston, when Major League Baseball and the Boston Red Sox honor Ice Bucket co-founders ... the challenge. MLB is donating $100,000 to further collaborative efforts among the ALS organizations ...
(Date:7/31/2015)... ... July 31, 2015 , ... Successful Import/Export ... http://www.fdanews.com/importexportprogram , Having FDA-regulated products held at ports costs time, money ... risking containment — or even destruction — of products, an FDA insider shows ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... a blog post that encourages the understanding and treatment of ankle sprains. A ... for in-home remedies. This can be dangerous if the condition augments and causes ...
Breaking Medicine News(10 mins):Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2
... SPRING HARBOR, N.Y. - In a variety ... stem cells have the potential to differentiate into a ... to a complete new organism. Stem cell research, ... biologists--reproductive biologists, cancer biologists, cell and developmental biologists, and ...
... Dermatologists emphasize treatment should be tailored to meet ... Ill., June 4 Based on an extensive review ... recognized psoriasis experts, the American Academy of Dermatology (Academy) ... and treatment of psoriasis with traditional systemic therapies. Recommendations, ...
... 4 Custom Spine announced today that Randal Clarke is ... Randy has been in the orthopedic medical device market ... for new products and building successful start-up organizations. ... representative for Zimmer, which was followed by a sales career ...
... PAUL, Minn., June 4 The Minneapolis-St. Paul office ... Marrow Donor Program to head the organization,s largest annual ... runs June 8-22, will work to reach a diverse ... advocates. For thousands of people with leukemia and other ...
... Pharmacy Management Technology, Will Offer Patients Any-Store Refills , ... LLC has selected PDX and affiliates Rx.com and NHIN as ... , , Albertson,s, LLC is replacing its current ... (EPS), unparalleled in efficiency, safety, and tools for ...
... before the current economic downturn, an American family filed for ... of them were insured. Over 60% of all bankruptcies in ... In an article published in the August 2009 issue of ... the first-ever national random-sample survey of bankruptcy filers shows that ...
Cached Medicine News:Health News:New interdisciplinary volume focuses on advances in stem cell research 2Health News:American Academy of Dermatology Issues New Guidelines For the Management of Psoriasis With Systemic Medications 2Health News:American Academy of Dermatology Issues New Guidelines For the Management of Psoriasis With Systemic Medications 3Health News:American Academy of Dermatology Issues New Guidelines For the Management of Psoriasis With Systemic Medications 4Health News:American Academy of Dermatology Issues New Guidelines For the Management of Psoriasis With Systemic Medications 5Health News:American Academy of Dermatology Issues New Guidelines For the Management of Psoriasis With Systemic Medications 6Health News:Custom Spine Welcomes Randal Clarke as Vice President of Sales 2Health News:Weber Shandwick Chosen By National Marrow Donor Program(R) To Head Awareness Campaign 2Health News:Weber Shandwick Chosen By National Marrow Donor Program(R) To Head Awareness Campaign 3Health News:Albertson's, LLC Selects PDX-NHIN-Rx.com to Provide Complete Pharmacy Management Solution 2Health News:Over 60 percent of all US bankruptcies attributable to medical problems 2
Used for common bile duct exploration. Supplied sterile in peel-open packages. Intended for one-time use....
... with the MAMMOTOME® HH (Hand ... invasive procedure using ultrasound imaging ... images to locate breast abnormalities, ... and map the area you ...
... Provides reliable strength for temporary wound ... which compliant and stretchable support material ... transudate is not required. Predictable absorption. ... be inert, nonantigenic, and nonpyrogenic. ,VICRYL ...
... Mesh plugs perform best when the ... contact with a smooth wall of highly ... means less tissue remodeling to help stabilize ... fills more of the defect with gentle ...
Medicine Products: